Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in &lt;i&gt;FGFR-&lt;/i&gt;Driven Urothelial Cancer

Facchinetti, Francesco; Hollebecque, Antoine; Brayé, Floriane; Vasseur, Damien; Pradat, Yoann; Bahleda, Rastislav; Pobel, Cédric; Bigot, Ludovic; Déas, Olivier; Arango, Juan David Florez; Guaitoli, Giorgia; Mizuta, Hayato; Combarel, David; Tselikas, Lambros; Michiels, Stefan; Nikolaev, Sergey I.; Scoazec, Jean‐Yves; Besse, Benjamin; Olaussen, Ken A.; Loriot, Yohann; Friboulet, Luc

doi:10.1158/2159-8290.23945343

2023

DOI: 10.1158/2159-8290.23945343

|View full text |Cite

Preprint

Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer

Francesco Facchinetti¹,

Antoine Hollebecque²,

Floriane Brayé³

et al.

Abstract: <p>IC50 values of Ba/F3 cells harboring FGFR3:TACC3 mutants exposed to eight selective FGFR inhibitors.</p>

Help me understand this report

View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome

Broghammer,

Korovina,

Gouda

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Background Focal adhesion signaling involving receptor tyrosine kinases (RTK) and integrins co-controls cancer cell survival and therapy resistance. However, co-dependencies between these receptors and therapeutically exploitable vulnerabilities remain largely elusive in HPV-negative head and neck squamous cell carcinoma (HNSCC). Methods The cytotoxic and radiochemosensitizing potential of targeting 10 RTK and β1 integrin was determined in up to 20 3D matrix-grown HNSCC cell models followed by drug screening and patient-derived organoid validation. RNA sequencing and protein-based biochemical assays were performed for molecular characterization. Bioinformatically identified transcriptomic signatures were applied to patient cohorts. Results Fibroblast growth factor receptor (FGFR 1–4) targeting exhibited the strongest cytotoxic and radiosensitizing effects as monotherapy and combined with β1 integrin inhibition, exceeding the efficacy of the other RTK studied. Pharmacological pan-FGFR inhibition elicited responses ranging from cytotoxicity/radiochemosensitization to resistance/radiation protection. RNA sequence analysis revealed a mesenchymal-to-epithelial transition (MET) in sensitive cell models, whereas resistant cell models exhibited a partial epithelial-to-mesenchymal transition (EMT). Accordingly, inhibition of EMT-associated kinases such as EGFR caused reduced adaptive resistance and enhanced (radio)sensitization to FGFR inhibition cell model- and organoid-dependently. Transferring the EMT-associated transcriptomic profiles to HNSCC patient cohorts not only demonstrated their prognostic value but also provided a conclusive validation of the presence of EGFR-related vulnerabilities that can be strategically exploited for therapeutic interventions. Conclusions This study demonstrates that pan-FGFR inhibition elicits a beneficial radiochemosensitizing and a detrimental radioprotective potential in HNSCC cell models. Adaptive EMT-associated resistance appears to be of clinical importance, and we provide effective molecular approaches to exploit this therapeutically.

show abstract

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome

Broghammer,

Korovina,

Gouda

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer

Abstract: <p>IC50 values of Ba/F3 cells harboring FGFR3:TACC3 mutants exposed to eight selective FGFR inhibitors.</p>

Cited by 1 publication

References 0 publications

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome

Contact Info

Product

Resources

About